Pharmaceutical - Anti-virals, Pricing

Filter

Current filters:

Anti-viralsPricing

Popular Filters

1 to 25 of 39 results

ViiV’s Triumeq offers added benefit for treatment-naive adults with HIV, says IQWiG

ViiV’s Triumeq offers added benefit for treatment-naive adults with HIV, says IQWiG

08-01-2015

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG), which had already assessed a…

Anti-viralsGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationTriumeqViiV Healthcare

Express Scripts says AbbVie’s Viekira Pak to be exclusive option for genotype 1 hepatitis C

Express Scripts says AbbVie’s Viekira Pak to be exclusive option for genotype 1 hepatitis C

22-12-2014

Express Scripts today announced an update to its National Preferred Formulary that will significantly…

AbbVieAnti-viralsExpress ScriptsGilead SciencesHarvoniPharmaceuticalPricingSovaldiUSAViekira Pak

Big savings on HIV drugs via pooled procurement expected by Global Fund

Big savings on HIV drugs via pooled procurement expected by Global Fund

12-12-2014

The Global Fund to Fight AIDS, Tuberculosis and Malaria is putting into place a new agreement for purchasing…

Anti-viralsFinancialGlobalHealthcarePharmaceuticalPricing

Bristol-Myers reveals access plan for hep C drug daclatasvir

03-11-2014

US Pharma major Bristol-Myers Squibb has recently revealed a commercial strategy for sales of its new…

Anti-viralsBristol-Myers SquibbdaclatasvirDaklinzaMarkets & MarketingPharmaceuticalPricing

Medivir concludes Swedish agreement on Olysio-based treatment for hepatitis C

Medivir concludes Swedish agreement on Olysio-based treatment for hepatitis C

31-10-2014

Swedish drugmaker Medivir says it has entered into an agreement with Swedish county councils regarding…

Anti-viralsJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalPricingRegulationSweden

UK NICE consults on draft guidance for hepatitis C drug Olysio

UK NICE consults on draft guidance for hepatitis C drug Olysio

18-09-2014

In draft guidance published today UK drugs watchdog the National Institute for Health and Care Excellence…

Anti-viralsJanssenJohnson & JohnsonOlysioPharmaceuticalPricingRegulationUK

Added benefit for certain patients found by IQWiG with Janssen’s Olysio

Added benefit for certain patients found by IQWiG with Janssen’s Olysio

15-09-2014

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

Anti-viralsGermanyJanssenJohnson & JohnsonOlysioPharmaceuticalPricingRegulation

Expensive new hepatitis C drugs are worth the investment

Expensive new hepatitis C drugs are worth the investment

21-07-2014

The debate over the high price of new Hepatitis C Virus (HCV) drugs has focused on the price per pill,…

Anti-viralsCVS CaremarkGilead SciencesHepatitis CPharmaceuticalPricingSovaldiUSA

Médecins Sans Frontières says countries are being priced out of HIV drugs and testing

Médecins Sans Frontières says countries are being priced out of HIV drugs and testing

21-07-2014

International medical humanitarian organization Médecins Sans Frontières has said that high prices…

Anti-viralsAntiretroviral drugHIVHIV/AIDSMSFPharmaceuticalPricing

IQWIG finds added benefit in adult patients for VIIV Healthcare’s Tivicay

27-05-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

Anti-viralsGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationTivicayViiV Healthcare

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

09-04-2014

Expensive treatments for broad patient populations are driving unprecedented growth in US spending on…

Anti-Arthritics/RheumaticsAnti-viralsMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricingUSA

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

ViiV Healthcare grants licence to Medicines Patent Pool to improve access to Tivicay

ViiV Healthcare grants licence to Medicines Patent Pool to improve access to Tivicay

02-04-2014

Viiv Healthcare, the HIV/AIDS joint venture of UK pharma giant GlaxoSmithKline, US drugmaker Pfizer and…

Anti-viralsGlobalPharmaceuticalPricingTivicayViiV Healthcare

Pharma Summit: AIDS activists picket to demand South African reform

Pharma Summit: AIDS activists picket to demand South African reform

14-03-2014

Delegates at The Economist’s Pharma Summit in London yesterday were greeted by AIDS activists picketing…

Anti-viralsFinancialLegalPharmaceuticalPricingSouth AfricaUK

New agreement with GSK provides new medicines, saves millions for New Zealand

New agreement with GSK provides new medicines, saves millions for New Zealand

11-12-2013

A new agreement with the local subsidiary of UK pharma giant GlaxoSmithKline by New Zealand’s Pharmaceutical…

Anti-viralsAsia-PacificGlaxoSmithKlineHealthcareHematologyNew ZealandPharmaceuticalPricingRespiratory and PulmonarySeretideSerevent Diskus

AHF sues Abbott and AbbVie for overcharging on AIDS drug pricing

AHF sues Abbott and AbbVie for overcharging on AIDS drug pricing

28-11-2013

In further legal action against drugmakers allegedly over pricing AIDS drugs in the USA, the AIDS Healthcare…

Abbott LaboratoriesAbbVieAnti-viralsKaletra TabletsLegalNorth AmericaNorvirPharmaceuticalPricing

AHF sues Johnson & Johnson over AIDS drug pricing

AHF sues Johnson & Johnson over AIDS drug pricing

01-11-2013

The Washington DC, USA-based AIDS Healthcare Foundation (AHF) has filed a law suit in the Superior Court…

Anti-viralsJanssenJohnson & JohnsonLegalNorth AmericaPharmaceuticalPricing

UK NICE final draft guidance on treatment for chronic hepatitis C

UK NICE final draft guidance on treatment for chronic hepatitis C

11-10-2013

The UK drugs watchdog the National Institute of Health and Care Excellence this morning confirmed its…

Anti-viralsEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferon

AHF sues GSK for failing to provide discounts on HIV/AIDS drugs

11-09-2013

The USA-based AIDS Healthcare Foundation (AHF) said yesterday (September 10) that it has filed a law…

Anti-viralsGlaxoSmithKlineLegalNorth AmericaPharmaceuticalPricing

In wake of Tivicay approval, MSF asks, "when will people in developing countries have access?"

13-08-2013

As the US Food and Drug Administration approved the new HIV drug Tivicay (dolutegravir) late Monday (The…

Anti-viralsdolutegravirGlobalHealthcarePharmaceuticalPricingTivicayViiV Healthcare

Roche strikes deal with Medicines Patent Pool on medicines access

05-08-2013

Swiss drug major Roche (ROG: SIX) has entered into an agreement with the Medicines Patent Pool, a Geneva,…

Anti-viralsMarkets & MarketingPharmaceuticalPricingRocheValcyte

UK's NICE recommends hepatitis C treatment for children

18-07-2013

In draft guidance published this week, the UK's drugs watchdog the National Institute for Health and…

Anti-viralsBiotechnologyEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferonPeg

UNITAID market power results in price cuts of up to 80% for HIV/AIDS, TB and malaria products

30-05-2013

UNITAID's approach to transform health product markets has delivered price reductions of up to 80% for…

Anti-viralsAntibiotics and Infectious diseasesGenericsGlobalHealthcarePharmaceuticalPricingTropical diseases

1 to 25 of 39 results

Back to top